Clinical trials update: endocrine and biological therapy combinations in the treatment of breast cancer

被引：20

作者：

Leary, Alexandra F. ^{[1
]}

Sirohi, Bhawna ^{[1
]}

Johnston, Stephen R. D. ^{[1
]}

机构：

[1] Royal Marsden Hosp, Dept Med, London SW3 6JJ, England

来源：

BREAST CANCER RESEARCH | 2007年 / 9卷 / 05期

关键词：

GROWTH-FACTOR-RECEPTOR; FARNESYL TRANSFERASE INHIBITORS; TYROSINE KINASE INHIBITOR; ESTROGEN-RECEPTOR; CELL-PROLIFERATION; PHASE-I; FARNESYLTRANSFERASE INHIBITOR; ADJUVANT TAMOXIFEN; ALPHA; ACTIVATION;

D O I：

10.1186/bcr1763

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

A greater understanding of the biological mechanisms responsible for de novo and acquired endocrine resistance has led to the rational design of clinical trials exploring the benefit of combining hormonal therapies with novel biological agents in an effort to enhance the efficacy of ER+ breast cancer treatment. These studies are increasingly including parallel biological analyses to elucidate the molecular characteristics of those tumors that are most likely to respond to specific targeted/endocrine combinations in an effort to develop a tailored approach to the management of individual patients. Unfortunately despite encouraging preclinical data, some of these combinations have yielded disappointing results in the clinical setting. This article will review the results of clinical trials of endocrine/biological combinations conducted in early and advanced breast cancer as well as provide an update on ongoing studies.

引用

页数：10

共 65 条

[61] Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer [J].

Vogel, CL ;

Cobleigh, MA ;

Tripathy, D ;

Gutheil, JC ;

Harris, LN ;

Fehrenbacher, L ;

Slamon, DJ ;

Murphy, M ;

Novotny, WF ;

Burchmore, M ;

Shak, S ;

Stewart, SJ ;

Press, M .

JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (03) :719-726

[62] Somatic mutation and gain of copy number of PIK3CA in human breast cancer [J].

Wu, GJ ;

Xing, MZ ;

Mambo, E ;

Huang, X ;

Liu, JW ;

Guo, ZM ;

Chatterjee, A ;

Goldenberg, D ;

Gollin, SM ;

Sukumar, S ;

Trink, B ;

Sidransky, D .

BREAST CANCER RESEARCH, 2005, 7 (05) :R609-R616

[63] A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer [J].

Xia, Wenle ;

Bacus, Sarah ;

Hegde, Priti ;

Husain, Intisar ;

Strum, Jay ;

Liu, Leihua ;

Paulazzo, Georgina ;

Lyass, Ljuba ;

Trusk, Patricia ;

Hill, Jason ;

Harris, Jennifer ;

Spector, Neil L. .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2006, 103 (20) :7795-7800

[64]

Yang XW, 2001, CANCER RES, V61, P7025

[65]

Yang XW, 2000, CANCER RES, V60, P6890

← 1 2 3 4 5 6 7 →